AI Hub Operations ROI: What Manufacturers Should Expect

Thesis

1. Operating leverage: fewer manual BV, PA, status-check, fax/OCR, and outbound-call touches for the same patient volume.
2. Patient conversion: faster starts, fewer abandoned prescriptions, better persistence, and cleaner escalation before a payer or affordability barrier stalls therapy.

The first value pool lowers hub cost. The second can be much larger economically, but it is harder to prove and easier to overclaim. This page is the automation diligence page for the hub cluster; use Hub Pricing Benchmarking for baseline pricing structure and Hub Services Buyer’s Guide for the broader RFP.

Where AI Fits in Hub Operations

Workflow	Strong AI fit	Proof to require
Benefit verification	Payer portal navigation, eligibility lookups, missing-info detection, reverification queues	Electronic success rate, manual fallback rate, error rate, payer-tier coverage
Prior authorization	Criteria extraction, packet assembly, status tracking, appeal workflow prompts	Determination rate, turnaround time, denial reason capture, appeal success, human review rules
Payer phone calls	Voice AI for repetitive payer/provider status calls	Call completion rate, escalation rate, QA sampling, payer exceptions, recorded-call governance
Intake and forms	OCR, eConsent checks, enrollment completeness, duplicate detection	Clean-case creation rate, rework rate, provider burden, patient consent controls
Engagement and adherence	Next-best action, channel timing, refill-risk prediction	Incremental persistence or refill lift vs. matched baseline, opt-out/complaint rates
Reporting	Data normalization, exception surfacing, field-team alerts	Data latency, auditability, source-of-truth hierarchy, export rights

Vendor Capability Matrix

Vendor / model	Current AI posture	Buyer diligence
AssistRx	Acquisition-led engagement layer through AllazoHealth, integrated with therapy-initiation and patient-support services.	Ask for lift by program type, not generic engagement claims; confirm where AI suggestions require human approval.
CareMetx	Post-Lash scale plus next-generation CRM, automation partnerships, and EHR/provider workflow assets.	Separate legacy Lash/TheraCom transition work from net-new AI capability; confirm which automation tools transferred or remain active.
EVERSANA	Enterprise AI Accelerator and commercialization-platform AI, including non-hub modules.	Require hub-specific proof; do not accept agency, MLR, or omnichannel AI results as evidence of BV/PA improvement.
ConnectiveRx	Public positioning around access, affordability, ShieldRx, and technology leadership; automation detail is less transparent.	Test whether automation applies to hub casework, copay controls, EHR awareness/adherence, or pharmacy workflows.
Infinitus Systems	Voice AI for payer and healthcare administrative calls, with company-reported scale metrics.	Validate call-completion, exception handling, payer coverage, QA process, and whether savings reduce the manufacturer’s fee.
Neon Health	AI-native patient-access workflow automation layer; early-stage funding and company-reported automation claims.	Treat as a focused automation layer, not a full hub substitute unless references prove staffed operations and exception governance.

Therapeutic-Area Fit

AI ROI is highest when workflows are repeatable, high-volume, and rule-bound. It is lower when every case requires clinical judgment, rare documentation, site coordination, or compassionate-use escalation.

Program type	AI ROI potential	Why
High-volume specialty / GLP-1-style PA	High	Large volume, recurring criteria, clear manual work reduction, measurable turnaround impact
Autoimmune / immunology	Medium to high	Payer-rule variation and specialty pharmacy handoffs create useful automation targets
Oncology buy-and-bill	Medium	Documentation and benefit checks matter, but clinical nuance and site economics limit straight-through automation
Rare disease	Medium	AI helps with tracking, document assembly, and outreach timing; human case management remains central
Cell and gene therapy	Low to medium	Scheduling, chain-of-identity, treatment-center readiness, REMS, and clinical escalation require high-touch operations

ROI Framework for Manufacturers

Input Variables

Input	Example Value	Source
Annual patient volume	5,000	Manufacturer forecast
Drug ASP	$80,000	WAC less discounts
Current PA approval rate	Current program baseline	Hub performance data
Current abandonment rate	Current program baseline	Hub performance data
Current time-to-therapy	Current program baseline	Hub performance data
Current hub unit cost	Current contract	Hub contract
Manual-touch rate	Current program baseline	Hub work queue / QA data
Rework / exception rate	Current program baseline	Hub work queue / QA data

AI-Augmented Scenario

Output	Traditional baseline	AI-augmented case	Delta to underwrite
Manual touches per case	Current level	Lower level	Labor savings and capacity release
First-cycle completion	Current level	Higher level	Less rework and fewer patient/provider delays
Time-to-therapy	Current median / percentile	Reduced median / percentile	Patient-conversion lift
Abandonment	Current level	Lower level	Incremental starts
Hub fee	Current FTE/transaction/patient model	New model after automation	Savings pass-through
Quality / complaint rate	Current level	No degradation	Guardrail against automation-driven friction

The key underwriting question is whether the vendor is offering a lower price, a better SLA, a performance guarantee, or merely a technology surcharge.

Contracting Requirements

• Baseline the current workflow before implementation: manual touches, turnaround time, rework, abandonment, escalation, and QA error rates.
• Define what counts as automated, AI-assisted, manually completed, and reworked.
• Require a human-review policy for clinical, adverse-event, complaint, appeal, and denial-risk workflows.
• State how labor savings are shared: fee reduction, performance credit, capacity redeployment, or vendor-retained margin.
• Preserve patient-level data export rights and audit logs for every AI-assisted decision or recommendation.
• Add a rollback plan if automation increases complaints, denials, missing-information loops, or provider burden.

Related Categories

• Hub Services & Patient Support Programs — Category market map and key players
• Prior Authorization & Reimbursement — PA vendor landscape

Related Concepts

• AI & Automation in Pharma Services — Broader AI landscape across all pharma services categories
• Hub Services Overview — Traditional hub operations that AI is augmenting
• Prior Authorization in Specialty Pharma — PA workflows as the primary AI automation target
• GLP-1 Receptor Agonists & Pharma Services — GLP-1 PA as the defining high-volume AI use case
• Hub Services Pricing Benchmarking — Traditional hub cost baselines for ROI comparison

Related Pages

Vendors:

• Infinitus Systems — Voice AI for healthcare administrative calls; validate payer coverage, exception handling, and fee pass-through.
• Neon Health — AI-native patient-access automation layer; validate staffed-operations depth and escalation governance before treating it as hub replacement.
• AssistRx — AllazoHealth acquisition adds AI-enabled engagement to the therapy-initiation workflow.
• EVERSANA — AI Accelerator and commercialization-platform AI; require hub-specific proof.
• CareMetx — Post-Lash hub operator where automation diligence should separate transition work from net-new AI capability.

Analyses:

• AI Disruption in Pharma Services — Market-level structural analysis
• Hub Services Market Analysis — Competitive landscape context

Implications

For manufacturers, AI hub ROI should be underwritten against two separate value pools: direct operating-cost reduction and incremental patient conversion. The direct savings are easiest to measure in PA/BV/status-check labor, but the larger economic case usually comes from faster starts, fewer abandoned prescriptions, and better persistence. RFPs should therefore require vendors to show baseline time-to-therapy, abandonment, PA approval, and escalation rates before claiming an AI lift; otherwise “80% automation” claims are not comparable across programs (see Hub Pricing Benchmarking, AI Disruption in Pharma Services, and the page’s Neon / Infinitus / AssistRx source set).

The contracting implication is that hub pricing should move away from pure FTE capacity toward blended FTE + transaction + performance constructs. Manufacturers should ask for automation pass-through economics: what share of labor savings reduces the fee, what share funds vendor technology investment, and what performance guarantees apply if automation increases rework or patient friction. For rare disease, oncology, and CGT programs, the right AI use may be narrow triage and document assembly rather than broad case-manager replacement.